The pharmacological treatment of heart failure in DCM patients with reduced LVEF follows the current guideline-directed therapies which includes angiotensin-converting enzyme (ACE) inhibitors (or Angiotensin receptor blockers (ARBs)), in association with beta-blockers, and mineralocorticoid antagonists [78]. This evidence concerns the gene ACE and familial dilated cardiomyopathy.